NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, News, & Analysis

+0.06 (+0.54 %)
(As of 06/24/2019 06:00 AM ET)
Today's Range
Now: $11.13
50-Day Range
MA: $10.77
52-Week Range
Now: $11.13
Volume185,046 shs
Average Volume269,393 shs
Market Capitalization$214.36 million
P/E RatioN/A
Dividend YieldN/A
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:EIGR



Sales & Book Value

Annual SalesN/A
Book Value$3.49 per share


Net Income$-52,390,000.00


Market Cap$214.36 million
Next Earnings Date8/9/2019 (Estimated)
OptionableNot Optionable

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) issued its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.95) by $0.05. View Eiger Biopharmaceuticals' Earnings History.

When is Eiger Biopharmaceuticals' next earnings date?

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August 9th 2019. View Earnings Estimates for Eiger Biopharmaceuticals.

What price target have analysts set for EIGR?

5 Wall Street analysts have issued 12-month price targets for Eiger Biopharmaceuticals' shares. Their predictions range from $26.00 to $47.00. On average, they anticipate Eiger Biopharmaceuticals' stock price to reach $36.60 in the next year. This suggests a possible upside of 228.8% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.

What is the consensus analysts' recommendation for Eiger Biopharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.

What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:
  • 1. LADENBURG THALM/SH SH analysts commented, "We are encouraged to see that the agency has recognized the unmet need of post-bariatric surgery patients that develop PBH, which is a chronic condition characterized by dangerously low postprandial blood glucose levels. By 2022, we estimate ~70,000 annual Roux-en-Y gastric bypass (RYGB) surgeries will be performed in the U.S. (stomach is cut to form a small pouch; connected directly to small intestine’s ileum), with ~25,000 developing PBH. We are modeling peak revenues of $200-250M in the U.S. and Europe, each. We continue to look for Eiger to secure a European partner after pivotal results and/or after EMA approval. The BTD status is timely, as Eiger management is to meet with the agency this summer for its End-of-Phase 2 meeting where it will discuss the pivotal study design, the dosing, duration, cohort size and other design details." (6/18/2019)
  • 2. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (5/1/2019)
  • 3. Wedbush analysts commented, ". Reiterate OW and $130 PT. FINCH 1 & 3 Ph3 filgotinib data, expected any day now, is an important catalyst for GLPG and partner GILD (Young, OW). Our thoughts on what to look for. The first filgotinib Ph3 study, FINCH 2, read out in Sept. ’18 and in our view suggested that filgotinib may have a best in class risk-benefit profile among the JAK inhibitors. In the data from the FINCH 1 & 3 studies (guided for 1Q19), we think investors will be focused on 1) how efficacy compares to other agents, most notably upadacitinib (ABBV, not- covered), 2) safety events such as thrombotic events/infections vs. placebo. For our detailed RA trial comp." (3/26/2019)

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

News stories about EIGR stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Eiger Biopharmaceuticals.

Who are some of Eiger Biopharmaceuticals' key competitors?

What other stocks do shareholders of Eiger Biopharmaceuticals own?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the folowing people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)
  • Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)
  • Mr. James P. Shaffer, Chief Bus. Officer (Age 52)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38)

Who are Eiger Biopharmaceuticals' major shareholders?

Eiger Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Interwest Venture Management Co. (3.99%), P.A.W. Capital Corp (0.99%), Fosun International Ltd (0.75%), Laurion Capital Management LP (0.59%), Tibra Equities Europe Ltd (0.17%) and Tocqueville Asset Management L.P. (0.12%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Jeffrey S Glenn, Joanne Quan, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

Which institutional investors are selling Eiger Biopharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Algert Global LLC, Fosun International Ltd, P.A.W. Capital Corp and Tocqueville Asset Management L.P.. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Which institutional investors are buying Eiger Biopharmaceuticals stock?

EIGR stock was acquired by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Tibra Equities Europe Ltd and Wedbush Securities Inc.. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Insider Buying and Selling for Eiger Biopharmaceuticals.

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $11.13.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $214.36 million. The biotechnology company earns $-52,390,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.View Additional Information About Eiger Biopharmaceuticals.

What is Eiger Biopharmaceuticals' official website?

The official website for Eiger Biopharmaceuticals is

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]

MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  335 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel